| Angela M Urmanski, PHARMD, BCOP | |
|
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
| (414) 805-3145 | |
| Not Available |
| Full Name | Angela M Urmanski |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Oncology |
| Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134494107 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835X0200X | Pharmacist - Oncology | 1243340 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela M Urmanski, PHARMD, BCOP 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: () - | Angela M Urmanski, PHARMD, BCOP 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-3145 |
News Archive
Over recent years, Zika virus has spread eastward from Africa and Asia, leading to an epidemic in the Americas. Now, researchers comparing American, Pacific and Southeast Asian subtypes of the virus in PLOS Neglected Tropical Diseases have concluded that the American-subtype strain has the highest ability to grow both in vitro and in vivo.
A new national poll from Harvard School of Public Health (HSPH) researchers found that a majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so. The poll, which examines the American public's response to the H1N1 vaccine shortage, is the fifth in a series of surveys of public views concerning the H1N1 flu outbreak undertaken by the Harvard Opinion Research Program at HSPH.
IP 751, a potent synthetic analog of a metabolite of THC-the principal active ingredient of marijuana-effectively suppresses pain and bladder overactivity in hypersensitive bladder disorders such as interstitial cystitis (IC), according to animal model study results presented today at the annual meeting of the International Continence Society.
Among men with prostate cancer who received care from the Veterans Affairs (VA) Health System, an equal-access health care system, African American men did not have more advanced disease at the time of diagnosis or die earlier than white men, unlike trends seen in the greater U.S. population of patients with prostate cancer.
Gilead Sciences, Inc. today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread.
› Verified 8 days ago
Robin L Berk, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1134 W North Ave, Third Floor, Milwaukee, WI 53205 Phone: 414-727-3005 | |
Kevin Bozymski, PHARMD, BCPS Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1155 N Mayfair Rd, Milwaukee, WI 53226 Phone: 414-955-8950 | |
Hanna Dehnert, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3003 W Good Hope Rd, Milwaukee, WI 53209 Phone: 414-540-9236 | |
Belaynesh Dejene Feleke, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5929 W Lisbon Ave, Milwaukee, WI 53210 Phone: 414-442-9233 | |
Ting Chen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3030 W Villard Ave, Milwaukee, WI 53209 Phone: 414-536-3378 | |
Matthew Olson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2920 W Dakota St, Milwaukee, WI 53215 Phone: 262-957-8239 | |
Michael Sean Stiewe, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3237 S 16th St, Milwaukee, WI 53215 Phone: 414-647-5043 |